Literature DB >> 12757250

Ivermectin.

George W Elgart1, Terri L Meinking.   

Abstract

Ivermectin is a potent antiparasitic drug and the first commercially available member of a new class of drugs (macrocyclic lactones) that has been approved for human use. Ivermectin has already proven to be highly effective in the elimination of river blindness as a public health burden. Side effects have been minor, and patient acceptance is good. Promising results in off-label applications for ectoparasitic infestations are increasingly important as resistance to topical therapy becomes more prevalent Ivermectin represents an advance in the therapeutic armamentarium and should be considered in appropriate cases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12757250     DOI: 10.1016/s0733-8635(02)00095-5

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  1 in total

1.  Isolation and identification of new macrocyclic lactones from a genetically engineered strain Streptomyces bingchenggensis BCJ60.

Authors:  Jiansong Li; Shaoyong Zhang; Hui Zhang; Haiyan Wang; Ji Zhang; Anliang Chen; Jidong Wang; Wensheng Xiang
Journal:  J Antibiot (Tokyo)       Date:  2016-10-26       Impact factor: 2.649

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.